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Abstract
The aberrant activity of Ras homologous (Rho) family small GTPases (20 human members) has 
been implicated in cancer and other human diseases. However, in contrast to the direct mutational 
activation of Ras found in cancer and developmental disorders, Rho GTPases are activated most 
commonly by indirect mechanisms in disease. One prevalent mechanism involves aberrant Rho 
activation via the deregulated expression and/or activity of Rho family guanine nucleotide 
exchange factors (RhoGEFs). RhoGEFs promote formation of the active GTP-bound state of Rho 
GTPases. The largest family of RhoGEFs is comprised of the Dbl family RhoGEFs with 70 human 
members. The multitude of RhoGEFs that activate a single Rho GTPase reflect the very specific 
role of each RhoGEF in controlling distinct signaling mechanisms involved in Rho activation. In 
this review, we summarize the role of Dbl RhoGEFs in development and disease, with a focus on 
Ect2, Tiam1, Vav and P-Rex1/2.
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Introduction
Ras homologous (Rho) family proteins (20 human members) comprise a major branch of the 
Ras superfamily of small GTPases,1 with RhoA, Rac1 and Cdc42 the most extensively 
studied and characterized.2 Rho GTPases specifically regulate actin organization, cell 
motility, polarity, growth, survival and gene transcription.3 Rho GTPases are binary switches 
that cycle between an active GTP-bound and an inactive GDP-bound state (Figure 1).4 Rho 
guanine nucleotide exchange factors (RhoGEFs) accelerate the intrinsic exchange activity of 
Rho GTPases to stimulate formation of Rho-GTP.5 Rho GTPase activating proteins 
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(RhoGAPs) stimulate the intrinsic GTP hydrolysis activity of Rho GTPases, resulting in the 
inactive GDP-bound state. Rho guanine nucleotide-dissociation inhibitors (GDIs) comprise a 
third class of regulatory proteins.6 RhoGDIs bind Rho GTPases in a GDP-bound state and 
also extract and sequester Rho GTPases from the cell membrane where Rho GTPases can be 
activated. Once activated, the GTP-bound GTPase then associates with effector targets that 
number over 100.7–9 In this review, we focus on the classical Dbl family RhoGEFs and their 
role in development and disease. In particular, we focus on the RhoGEFs with the best 
validated roles in cancer (Vav1/2/3, Ect2, Tiam1/2, P-Rex1/2) and their analyses in cell 
culture, mouse models and human cancers.
The discovery of RhoGEFs: diverse in numbers and structure
The first RhoGEF was identified initially as an oncogene in mammalian cells (Table 1 and 
Figure 2). Using the same NIH 3T3 mouse fibroblast focus formation assay that led to the 
discovery of mutant Ras in human cancer,10 analysis of genomic DNA isolated from a 
human diffuse B-cell lymphoma resulted in the discovery of the DBL oncogene that encoded 
an N-terminally truncated and activated protein.11 Dbl was also detected earlier as an 
oncogene that caused the tumorigenic growth of NIH 3T3 cells after transfection with 
genomic DNA from the MCF-7 human breast carcinoma cell line (designated mcf2)12, and 
only later was it determined to be identical to Dbl.13 Dbl was subsequently shown to 
catalyze the GTP/GDP exchange activity of Cdc42.14 Additional NIH 3T3 focus formation 
and related biological assays identified Dbl-related proteins, in particular Vav, Tiam1 and 
Ect2 (Table 1 and Figure 2). That RhoGEFs were discovered initially as oncoproteins 
provided the first suggestion that Rho GTPases may also have a function in oncogenesis.
Dbl and the Dbl-related proteins share a ~200 amino acid catalytic Dbl homology (DH; also 
called RhoGEF) domain and an immediately adjacent regulatory ~100 amino acid pleckstrin 
homology (PH) domain5 (Figure 3). Additional RhoGEFs with this tandem DH-PH domain 
structure were identified by genetic and biochemical approaches and by in silico database 
searches. There are 70 human Dbl family RhoGEFs, many of which have conserved 
orthologs found in all vertebrate species and in invertebrates, including Drosophila, C. 
elegans, S. cerevisiae and S. pombe. The nomenclature for many Dbl RhoGEFs is 
complicated by the different names used in independent discoveries, by different names for 
orthologs of different species, by the existence of different gene products due to alternative 
RNA splicing and by establishment of the ARHGEF gene family nomenclature by the 
HUGO Gene Nomenclature Committee (http://www.genenames.org/genefamilies/
ARHGEF). We have compiled a summary of Dbl RhoGEF nomenclature, based on the 
names most commonly used in the literature together with the additional names used for 
each RhoGEF (Supplementary Table 1).
In addition to their common structural elements that define them as RhoGEFs, there are 
some distinctive features that mark individual RhoGEF proteins. Two RhoGEFs possess 
tandem sets of DH-PH domains (Trio and Kalirin) and four RhoGEFs (Tuba1, 2, 3 and 
ARHGEF33) lack an apparent PH domain (Figure 3).5 Dbl RhoGEFs also diverge 
significantly in the N- and C-terminal sequences flanking the DH/PH domains. These 
flanking sequences commonly contain a diversity of protein-protein or protein-lipid 
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interaction domains and motifs whose functions are to regulate intrinsic RhoGEF catalytic 
activity, determine subcellular localization and/or facilitate complex formation with other 
proteins (Figure 3).
This diversity in flanking non-RhoGEF sequences distinguishes the regulation and role of 
RhoGEFs that otherwise activate the same set of Rho GTPases. For example, extracellular 
stimuli that first activate RhoGEFs downstream of G-protein coupled receptors (GPCRs) and 
subsequently cause activation of G protein beta-gamma subunits (P-Rex), of Ras (Tiam1), or 
of Src family tyrosine kinases (Vav) can all converge on downstream Rac1 activation 
through distinct RhoGEFs (Figure 4). These flanking sequences may also regulate 
subcellular localization and activation of spatially distinct cellular pools of Rho GTPases, 
leading to their utilization of distinct effectors. Finally, these flanking sequences may 
facilitate scaffolding functions for RhoGEFs that can further influence the effectors 
activated. For example, Tiam1 possesses a PH-CC-Ex globular domain15 that acts as a 
membrane targeting and protein-protein interaction domain.16–19 This scaffolding function 
can then influence the effector utilization of the activated Rho GTPase.20,21
Humans also possess a second structurally and mechanistically distinct22 class of RhoGEFs, 
the dedicator of cytokinesis or DOCK family (11 human members) that act as GEFs for Rac 
and/or Cdc42, but not RhoA.23–25 DOCK RhoGEFs lack primary sequence homology with 
the DH domain and instead are characterized by a conserved Dock-homology region-2 
(DHR-2; also called DOCKER, CZH2) that serves as the RhoGEF catalytic domain. DHR-2 
domains exhibit no primary sequence homology to DH domains. Although plant species 
possess Rho-like GTPases (Rho of plants; Rop)26, and are regulated by DOCK RhoGEFs, 
RhoGAPs and RhoGDIs homologous to mammalian RhoGAPs27, they lack Dbl RhoGEFs. 
Instead, RopGEFs possess a structurally distinct plant-specific Rop nucleotide exchanger 
(PRONE) catalytic domain.28,29 Finally, although there are no Rho orthologs in prokaryotes, 
pathogenic bacteria possess effector proteins that can regulate their mammalian host Rho 
GTPases in part by mimicking the function of mammalian RhoGEFs.30,31
RhoGEFs and development
The combined number of human Dbl and DOCK RhoGEFs greatly exceeds the number of 
Rho GTPases, suggesting apparent redundancy in RhoGEF function. This is particularly 
striking for RhoA, where at least 28 Dbl RhoGEFs can activate this single GTPase (Figure 
3). With six Rho GTPases constitutively GTP-bound and active, and not believed to be 
regulated by RhoGEFs (Rnd1-3, RhoH/TTF, RhoBTB1/2)32, the apparent redundancy in 
RhoGEFs is even more striking.
One approach to evaluate this apparent functional redundancy has been the generation of 
mice deficient in one or more RhoGEFs, which additionally addresses their involvement in 
development. The role of at least 26 Dbl family RhoGEFs in mouse development has been 
evaluated (Table 2), with only four (Sos1, Trio, AKAP13 and Ect2) found to be 
essential.33–36 However, these proteins all possess other functions independent of their 
RhoGEF catalytic activities, and embryonic lethality may not be due specifically to loss of 
the RhoGEF function. For example, when only the AKAP13 RhoGEF domain was 
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disrupted, no lethality was seen, indicating that AKAP13 RhoGEF activity is not required 
for mouse development.37 AKAP13 is also a scaffolding protein that associates with the 
regulatory subunit of protein kinase A to spatially regulate its substrate utilization. AKAP13 
additionally interacts with protein kinase C and D isoforms and with heterotrimeric Gα 
subunits; whether any of these interactions are specifically required during development 
remains to be determined. Sos1 is also a RasGEF activated downstream of receptor tyrosine 
kinases. Trio contains a serine/threonine kinase domain in addition to its two distinct DH-PH 
RhoGEF domains. Although Ect2 has no other known catalytic function aside from its 
RhoGEF activity, there are Ect2 non-RhoGEF sequences shown to be important for 
regulation of cytokinesis in vitro.38 Below we provide a summary of the developmental roles 
of RhoGEFs that have additional roles in cancer.
Ect2
Ect2 (Epithelial Cell Transforming Sequence 2) was originally discovered as an oncogene 
that transformed NIH 3T3 cells.39 However, the Ect2 protein found to transform these 
fibroblasts was a truncated version of the full-length protein, formed during DNA 
manipulation in vitro (Figure 4). The N-terminus of Ect2 contains two regions that are 
homologous to XCCR1 and Clb6 domains that have functions in the DNA damage response 
and cell cycle regulation, respectively. However, while required for Ect2 support of 
cytokinesis,38 no specific functions have been ascribed to these sequences. The N-terminus 
also contains two tandem BRCA1 C-terminal (BRCT) domains that have auto-
inhibitory40,41 and phosphoprotein binding functions42,43 and two nuclear localization 
sequences (NLSs).44 The central catalytic portion of Ect2 consists of the tandem DH-PH 
domains. Finally, the C-terminal sequence of full-length Ect2 has no known domains or 
motifs but is required for the transforming activity of N-terminally truncated Ect2, and was 
recently implicated in modulating the stability of full length Ect2 protein.41,45,46 BRCT 
domains are not found in any other RhoGEFs and instead are found primarily in proteins 
involved in the DNA damage response network associated with cell cycle checkpoint 
functions.47,48 Although analyses of full length recombinant Ect2 protein indicate that it is 
selective for RhoA and its related isoforms (RhoB and RhoC) in vitro, cell-based studies 
suggest that Ect2 can also regulate Rac and Cdc42 activity.45
Recently we showed that Ect2-deficient mice are not viable.36 Whereas heterozygous 
Ect2+/− mice displayed normal development and lifespan, no Ect2−/− embryos were found at 
birth or as early as embryonic day 8.5. Our subsequent characterization of the defect in vitro 
demonstrated that isolated homozygous Ect2−/− blastocysts displayed abnormal outgrowth at 
day E3.5, indicating that Ect2 is required for peri-implantation development. The 
requirement for Ect2 at such an early stage of development suggests that it may play a key 
role in nearly all cells. Unlike a majority of Dbl RhoGEFs, there are no Ect2-related 
isoforms, which perhaps is a basis for its essential requirement in development.
The best-characterized normal function of Ect2 is its role in cytokinesis.40 Ect2 has been 
shown to regulate RhoA during cytokinesis49, the final step in both meiosis and mitosis. 
Therefore, it is likely that Ect2 is required for development because of its key role in normal 
cell division. Consistent with this possibility, a deficiency in MgcRacGAP (RacGAP1), a 
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RhoGAP that facilitates Ect2 localization to the central spindle during cytokinesis, also 
produced a similar embryonic lethality phenotype.50 Thus, despite the existence of at least 
27 other RhoGEFs that can activate RhoA (Figure 3), an Ect2 deficiency cannot be 
compensated for by other RhoGEFs to promote cytokinesis. However, since the Ect2 
sequences flanking the DH-PH module can serve scaffolding functions and facilitate protein 
interactions, it is possible that non-GEF functions contribute to the critical role of Ect2 in 
development. A definitive resolution of this issue will require analyses of mice that harbor a 
RhoGEF-dead Ect2 allele.
Tiam1
Tiam1 (T-cell Lymphoma Invasion and Metastasis 1) was found by retroviral insertional 
mutagenesis of T lymphoma cells and then screened for invasiveness.51 Tiam1 contains a 
PH domain followed by a coiled-coil motif and extra region (Ex) that together comprise a 
protein- and membrane-binding domain,15 a Ras-binding domain (RBD),52 a PSD-95/DlgA/
ZO-1 (PDZ) domain, then the tandem DH-PH domains (Figure 4). Although the exact 
mechanism(s) of Tiam1 activation is not clear, it is apparent that it can be regulated through 
intramolecular inhibition (coiled-coil motif with the DH domain), protein-protein 
interactions (Ras binding), and cellular localization (phospholipids with the PH domain) 
(Figure 4). Tiam1 is a Rac-selective GEF and was also shown to function as an effector of 
Ras.52 Although Rac1 deficiency causes severe embryonic lethality,53 Tiam1 is non-essential 
for mouse development.54 Thus, other GEFs that activate Rac can compensate for Tiam1 
loss-of-function, for example the related Tiam2 protein (37% overall identity, 71% DH 
domain identity).55,56
P-Rex1/2
P-Rex1 (PtdIns(3,4,5)P3-dependent Rac Exchanger) was discovered by purifying proteins 
from the cytosol of neutrophils and assaying for proteins that activate Rac1 in the presence 
of phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3/PIP3).57 Two different groups 
of researchers identified P-Rex2 by searching for proteins with sequence identity to P-
Rex1.58,59 P-Rex1 and P-Rex2 are very similar proteins (58% identity) that share amino-
terminal DH-PH domains, followed by two Dishevelled/Egl-10/Pleckstrin (DEP) and two 
PDZ domains, and then a C-terminal sequence that displays homology to inositol 
polyphosphate-4-phosphatase (IP4P) (Figure 4). P-Rex1 and likely P-Rex2 are both 
regulated through GPCR activation and Gβγ activation and phosphoinositol 3-kinase (PI3K)-
stimulated formation of PIP3. P-Rex1 function is attributed primarily to Rac activation, 
although P-Rex1 can also activate Cdc42 and other Rho family GTPases in biochemical 
assays.57
P-Rex1-deficient mice are healthy and viable but weigh less, with significantly smaller 
livers, than P-Rex1+/+ mice60. It was also shown that P-Rex1−/− mice on a pure C57BL6 
background displayed a “white belly”, white feet and tail, a phenotype with 100% 
penetrance.61 This phenotype was caused by a defect in melanoblast migration. The belly, 
feet, and tail are the most distal points of melanoblast migration from the neural crest during 
mouse embryogenesis, leading to the anatomical pattern of this pigmentation defect.
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P-Rex2 has two splice variants: a larger product that is very similar to P-Rex1 (P-Rex2a) and 
a smaller product (P-Rex2b) that does not contain the IP4P homology region. Whereas P-
Rex1 is expressed in peripheral blood leukocytes, neither of the P-Rex2 variants is present 
there. Instead P-Rex2a is found predominantly in skeletal muscle, intestine, and brain, 
whereas P-Rex2b is found only in heart.59
P-Rex2-deficient mice are viable and fertile with normal appearance and weight. However, 
P-Rex2−/− mice displayed a mild defect with motor coordination that worsens with age.62 
Furthermore, the P-Rex1−/− P-Rex2−/− double knockout mice exhibited defects in motor 
activity, posture, and gait consistent with cerebellar dysfunction that are stronger compared 
to the P-Rex1−/− or P-Rex2−/− single knockout mice.62
Vav1/2/3
Vav1 (named after the sixth letter in the Hebrew alphabet) was also discovered initially as an 
oncogene that caused growth transformation of NIH 3T3 cells. 63,64 Vav1-containing DNA 
was isolated from a human esophageal carcinoma, and the transforming variant also 
contained an N-terminal truncation of sequences upstream of the DH-PH domains. Two 
highly related isoforms, Vav2 and Vav3, share significant sequence identity (51 and 58% 
identity, respectively) and domain structure with Vav1 (Figure 4).65–68 Vav1/2/3 all contain 
the following domains: calponin homology (CH), an acidic (Ac) region, DH-PH, and a 
cysteine-rich zinc finger domain (C1) followed by a Src homology-2 and -3 (SH3-SH2-SH3) 
adaptor cassette69 (Figure 4). The active site of the DH domain is autoinhibited by a helix in 
the Ac region of Vav. Src and Syk kinases relieve the autoinhibition by phosphorylation of 
tyrosine 174 within the helix. Furthermore, the inhibitory conformation of the Ac region is 
stabilized through interactions of the CH domain with the Ac region and the DH-PH 
domains. Thus, maximal GEF activity of Vav is achieved in a multi-step process wherein the 
initial Src-dependent phosphorylation events that disrupt CH domain interactions are 
followed by phosphorylation on tyrosine 174.70,71 Although Vav function is attributed 
mainly to its ability to activate Rac, Vav proteins can also activate RhoA, Cdc42 and RhoG 
(Figure 4).
Vav2 and Vav3 are broadly expressed, whereas Vav1 is largely restricted to hematopoietic 
cells under normal conditions.72 Vav proteins are critical for the regulation of hematopoietic 
cell signaling by linking intracellular signaling to multi-subunit immune-recognition 
receptors (MIRRs).73 Vav1-deficient mice are viable but display a range of defects in the 
immune system, with the most severe defects found in T cell development and activation. By 
comparison, Vav2 deficiency did not perturb T cell development, and double knockout 
Vav1/2−/− mice exhibited similar T cell defects as seen in Vav1-deficient mice, indicating 
that Vav2 has no major function in T cell development in the absence of Vav1. In contrast, 
although Vav3-deficient mice also showed normal T cell development, combined deficiency 
of both Vav1/3 significantly exacerbated the T cell defect seen with Vav1 deficiency alone, 
indicating partially redundant roles for these two isoforms in T cell function. Finally, while 
combined Vav2/3 deficiency also showed no T cell abnormalities, the combined Vav1/2/3 
deficiency (viable, no gross organ abnormalities) showed a severe impairment in T cell 
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development, with no functional T cells, demonstrating that Vav2 can have a compensatory 
function in the absence of both Vav1 and Vav3.
Nonoverlapping B cell defects were observed in mice deficient in either Vav1 (B1 cell 
reduction, partial decrease in B cell proliferation upon B cell receptor (BCR) cross-linking) 
or Vav2 (reduced BCR responses). In contrast, combined Vav1/2 deficiency showed severe B 
cell maturation and response defects, demonstrating their nonredundant roles in B cell 
biology.74,75 Finally, mice deficient in all three Vav genes displayed additional B cell 
developmental defects absent in Vav2/3−/− double knockout mice.76 Thus, the Vav isoforms 
support both distinct and redundant functions in T and B cell development and activities, 
several of which cannot be compensated by other RhoGEFs.
RhoGEFs and cancer
The three Ras proteins (H-Ras, K-Ras4A/B, and N-Ras) are the founding members of the 
Ras superfamily of small GTPases1 and together they comprise the most frequently mutated 
oncoprotein family in human cancer (33%; http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/).10,77 However, with the exception of the recently described mutational 
activation of Rac1 in melanoma78,79, Rho family GTPases have not been reported to be 
mutated frequently in human cancer. Nevertheless, there is substantial experimental evidence 
that aberrant Rho GTPase function can contribute to cancer cell proliferation, invasion and 
metastasis.80 Instead, Rho GTPases are aberrantly activated more commonly by indirect 
mechanisms in cancer. These mechanisms include altered Rho localization mediated by 
GDIs; increased RhoGEF and/or decreased RhoGAP activity; altered gene expression of 
Rho GTPases, RhoGEFs, RhoGAPs, and RhoGDIs (Figure 1), and alternative splicing to 
generate constitutively active Rho GTPase isoforms (e.g., Rac1b).81,82
As mentioned above, although Dbl, Ect2 and Vav were identified originally as oncoproteins 
due to activation by N-terminal truncation, these altered RhoGEFs arose as an artifact of the 
DNA isolation/transfection procedure.83 Surprisingly, despite their potent transforming 
activities when assayed in NIH 3T3 mouse fibroblasts, such truncated, activated Dbl 
RhoGEFs have not been identified in human cancers. Instead, other mechanisms that lead to 
the deregulated expression and/or activation of full length RhoGEFs have been identified. 
Recent reviews have provided more comprehensive overviews of RhoGEF activation in 
cancer.4,84,85 Therefore, we have focused on the four Dbl RhoGEFs with the strongest 
evidence for their involvement in cancer growth (Supplementary Table 2) and have 
summarized representative studies for each below.
Ect2
Ect2 gene and/or protein overexpression has been described in glioblastoma,86–88 non-small 
cell lung cancer (NSCLC),89,90 esophageal,90 pancreatic,91 oral squamous cell,92 colorectal 
carcinomas,93 and other cancers (Supplementary Table 2).
The ECT2 gene is located in a region of chromosome 3q26 that is frequently altered in 
human tumors.94 Ect2 overexpression was associated with gene amplification in NSCLC, 
and this also correlated with an increase in the copy number of the gene encoding protein 
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kinase C iota, PKCi (PRKCI).89 Ect2 knockdown was associated with decreased Rac1 
activation, and constitutively activated Rac1 could compensate for the loss of Ect2, 
implicating this Rho GTPase in Ect2-dependent NSCLC anchorage-independent growth and 
invasion in vitro. Interestingly, the role of Ect2 in NSCLC was independent of Ect2 normal 
function in cytokinesis. Depletion of Ect2 expression in NSCLC did not result in any 
proliferation or multi-nucleation defects, phenotypes associated with Ect2 loss in normal 
cells.36
One mechanism that may account for a non-cytokinesis role for Ect2 in driving cancer 
growth under some conditions involves altered subcellular localization. Ect2 is one of two 
Dbl RhoGEFs (the other is Net1) with a nuclear-restricted localization in interphase cells. 
Fields and colleagues described regulation of NSCLC tumor growth and invasion through 
mislocalization of Ect2 to the cytoplasm, where it binds to a PKCi-Par6 complex to activate 
Rac1.89 They found that PKCi phosphorylated Ect2 at residue T328 adjacent to the Ect2 
nuclear localization sequences (NLSs), and this was associated with Ect2 cytosolic 
mislocalization. Furthermore, a T328D phosphomimetic but not a T328A phosphodeficient 
Ect2 mutant could rescue loss of endogenous Ect2 to restore lung tumor cell growth and 
invasion in vitro. That cytoplasmic mislocalization is an important mechanism of Ect2 
activation in cancer is consistent with the earlier observation that disruption of the Ect2 NLS 
motifs activated the transforming activity of full length Ect2 when evaluated in NIH 3T3 
fibroblasts.44 Cytoplasmic Ect2 may then cause spatially inappropriate Rho GTPase 
activation to drive cancer growth.
Two studies showed that Ect2 expression correlated with poor prognosis in glioma patients 
and that Ect2 was important for glioma cell proliferation, migration, and invasion in 
vitro.87,88 However, acute depletion of Ect2 expression by siRNA in giloma tumor cell lines 
showed an increase in multinucleation, characteristic of a defect in cytokinesis. Therefore, 
the acute decrease in proliferation, migration and invasion may have been caused by the 
inability of cells to complete mitosis. In contrast, sustained shRNA depletion of Ect2 did not 
suppress proliferation in vitro, but orthotopic xenograft tumor growth was impaired and 
associated with increased mouse survival.95 Thus, tumor cells may adapt to acute Ect2 loss, 
such that Ect2-dependent long-term tumor growth is independent of the role of Ect2 in 
cytokinesis.
In summary, future studies to determine whether conditional loss of Ect2 ablates tumor 
growth in mouse models will provide further assessment of the driver function of Ect2 
overexpression in cancer. Also, whether the mislocalization of Ect2 to the cytoplasm seen in 
NSCLC is the basis for a non-cytokinesis function that supports cancer cell growth will be 
important to evaluate in other human cancers. The potent oncogenic activities of the 
originally discovered N-terminally truncated Ect2, lacking the nuclear localization 
sequences, provides strong evidence that simple mislocalization may be an important driver 
of Ect2 activation in cancer. However, despite the implication of Ect2 as a driver in a variety 
of human cancers, the absence of any detection of N-terminally truncated Ect2 in human 
cancers argues that this cytoplasmic mislocalization mechanism may not hold true in the 
patient. In support of this possibility, in our own studies where we have established driver 
functions of full length Ect2 in ovarian and colorectal cancers, we have not found evidence 
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for cytoplasmic mislocalization as the basis for the aberrant Ect2 function in these cancers 
(unpublished observations).
P-Rex
The first cancer-driving role of P-Rex1 was described in prostate cancer.96 P-Rex1 protein 
expression was elevated in metastatic but not primary prostate tumor cell lines and tumor 
tissue. RNAi silencing of P-Rex1 expression reduced Rac activity, and migration and 
invasion in vitro.
PREX1 mRNA overexpression has also been associated with breast cancer, in particular the 
estrogen receptor-positive luminal subtype and, to a lesser degree, HER2-positive tumors.97 
Suppression of P-Rex1 expression was found to reduce HER2-stimulated Rac1 activation, 
motility, invasion, and tumorigenic growth.97,98
Increased P-Rex1 protein expression has also been seen in human melanoma tissue and cell 
lines relative to normal melanocytes,61 and RNAi suppression reduced Matrigel invasion of 
human melanoma cell lines. High P-Rex1 protein expression was associated with increased 
metastatic potential in immunocompromised mice. To assess a role for P-Rex1 in melanoma 
progression, P-Rex1-deficient mice were crossed to a mouse model of primary and 
metastatic melanoma (Tyr:NRasQ61K/INK4a−/−). Surprisingly, in contrast to the breast 
tumor studies, P-Rex1 deficiency did not reduce the incidence or latency of primary tumor 
formation. However, a significant reduction in metastasis was seen. While a mechanistic 
basis for these distinct roles for P-Rex1 in breast versus skin cancer progression has not been 
determined, one logical speculation is that this may reflect tissue type or genetic context 
differences in P-Rex1 function. More provocatively, it may reflect the differential activation 
of other Rho GTPases, aside from Rac1 (e.g., Cdc42), that then contribute to aberrant P-
Rex1-dependent functions in breast versus melanoma growth and tumor progression.
Recently, in a whole-genome sequence analysis of melanoma, non-synonymous mutations in 
PREX2 were found with a 14% frequency in a cohort of 107 human melanomas.99 The 
mutations occurred throughout the gene, including interchromosomal translocations and 
nonsense mutations, with some encoding C-terminally truncated protein products due to 
premature termination codons. To assess the biological relevance of these mutations, P-Rex2 
truncation or missense mutants were ectopically expressed in TERT-immortalized, mutant 
NRAS-expressing human melanocytes and shown to accelerate tumor formation in nude 
mice.
At least one P-Rex2 splice variant can promote cancer growth through a mechanism 
independent of its RhoGEF function.100 P-Rex2a can directly bind and inhibit the lipid 
phosphatase activity of the PTEN tumor suppressor, thereby causing activation of PI3K and 
Akt and subsequent stimulation of pro-growth and survival pathways. P-REX2A mRNA is 
preferentially overexpressed in PTEN-wildtype, PIK3CA-mutant breast tumors. Depleting 
P-Rex2a in PTEN-wildtype and PIK3CA-mutant MCF-7 breast cancer cells reduced 
phosphorylated AKT and cell growth in vitro.
Cook et al. Page 9













The aberrant activation of both P-Rex1 and P-Rex2 in melanoma, together with the frequent 
mutational activation of their key substrate Rac1 in melanoma,78,79 provides perhaps the 
most compelling evidence for a critical driver function of a Rho small GTPase in cancer. 
Determining which effector(s) may then drive Rac1-dependent melanoma growth will be an 
important next step in these studies.
Tiam1
Tiam1 mRNA and/or protein overexpression has been described in many cancers that 
include melanoma,101 breast,102,103 colon,104,105 prostate,106 and renal cell carcinoma107 
(Supplementary Table 2).
A role for Tiam1 in tumorigenesis has been evaluated in several mouse models of cancer. 
First, the consequence of Tiam1 deficiency was evaluated using the classical two-stage 
chemical carcinogenesis model for the initiation and promotion of cutaneous tumors.54 
Tumor formation is induced using a single application of the mutagen 7,12-
dimethylbenz[a]anthracene (DMBA), which is then followed by repeated applications of 
phorbol 12-myristate 13-acetate (PMA) tumor promoter. This treatment results in mutational 
activation of HRAS(Q61L) and the formation of benign papillomas that can progress to 
squamous cell carcinomas (SCC). Both the incidence of SCC formation and growth of SCC 
tumors were reduced in Tiam1−/− mice. Thus, TIam1 is an important contributor to H-Ras-
induced SCC tumor growth. These results, together with the identification of Tiam1 as an 
effector of Ras52 and findings that Rac1 deficiency reduced mutant K-Ras-induced lung and 
pancreatic tumor formation56,108, all support Tiam1 as an important effector of Ras-driven 
cancer growth. Conversely, for those tumors that did arise, Tiam1 deficiency enhanced 
metastatic growth. Thus, while Tiam1 was required for tumor initiation and progression, it 
was antagonistic for malignant progression in these models.
The role of Tiam1 has also been evaluated in a mouse model of colon cancer, the Apc Min 
(multiple intestinal neoplasia) mice that harbor a truncated and loss-of-function mutant of 
the Apc tumor suppressor. Absence of Tiam1 resulted in significantly reduced formation and 
growth of polyps, but in enhanced invasion of malignant intestinal tumors.109
Finally, Tiam1 deficiency reduced mammary tumor initiation and reduced metastasis in 
transgenic mice whose tumors are driven by mouse mammary tumor virus (MMTV) 
promoter-regulated mutant ErbB2/Neu. However, it had no effect on the growth of 
mammary tumors in MMTV-Myc transgenic mice.110 Interestingly, although Tiam1 was 
originally discovered for its ability to promote T cell invasion in vitro51, in some tissues it 
has also been shown to inhibit progression to malignant growth.
In patients, increased Tiam1 protein expression was found in a subset of colon tumors104, 
and RNAi suppression reduced the growth of colon cancer cell lines in vitro and in 
vivo.109,111 Tiam1 overexpression was found to be inversely proportional to the degree of 
promoter methylation.105 In a small panel of breast cancer patient samples, Tiam1 protein 
expression levels were higher in grade III compared with grade II tumors102 and Tiam1 
mRNA levels were significantly higher in tumour tissue from breast cancer patients who 
died from their disease compared with those who survived.112 However, in another study, 
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Tiam1 protein expression levels decreased with the progression of breast carcinomas.103 The 
reasons for these opposing findings remain unclear but may be related to different patient 
populations whose diseases are driven by distinct mechanisms.
Much less is known regarding the involvement of Tiam2 in cancer. TIAM2 encodes two 
isoforms, one similar in structure to Tiam1 (designated long; Tiam2L), and another lacking 
N-terminal sequences upstream of the DH domain (designated short; Tiam2S).56 
Interestingly, whereas mRNA for both isoforms could be detected in hepatocellular 
carcinoma (HCC), only the short isoform of Tiam2 protein was detected.113 Finally, 
although neither Tiam2S mRNA nor protein was detected in normal liver, HCC tumors and 
cell lines expressed elevated levels of Tiam2S protein, and further ectopic expression of 
Tiam2S enhanced the tumorigenic growth of an HCC cell line.
In summary, while altered Tiam1/2 expression has been observed in a variety of human 
cancers, the most compelling evidence for a driver function in cancer comes largely from 
model studies, where Tiam1 can either promote tumor progression or conversely antagonize 
invasion. The basis for these seemingly opposing roles for Tiam1 is unclear, especially since, 
as described above, it is the gain-of-function of another Rac-selective GEF (P-Rex1) that is 
essential for metastatic but not primary melanoma tumor growth.61 However, another 
possible explanation comes from the observation that Tiam1-Rac signaling restored E-
cadherin-mediated adhesion in MDCK canine kidney epithelial cells, thereby reducing cell 
migration.114 Further, since remodeling of cell-cell junctions is critical for tumor cell 
invasion, Tiam1 activity may have opposing consequences in cells invading individually 
versus collectively. Whether these in vitro findings provide the explanation for the 
antagonistic role of Tiam1 in tumor cell invasion and metastasis remains to be determined.
Vav1
Although the Vav1 isoform originally identified by its ability to transform NIH 3T3 cells 
was activated by N-terminal truncation, and equivalent truncations of Vav2 and Vav3 also 
convert them to transforming proteins (Figure 4),67,115,116 no N-terminally truncated Vav 
proteins have been identified in cancer. Instead, Vav1 overexpression has been described in a 
spectrum of cancers, including neuroblastoma,117 lung,118 pancreatic,119 metastatic 
melanoma120 and B-cell chronic lymphocytic leukemia.121 Additionally, persistent 
phosphorylation has also been seen in some cancers, consistent with the observation that N-
terminal phosphorylation can reversibly disrupt the N-terminal autoinhibitory function to 
activate Vav1.
Although Vav1 expression is normally restricted to hematopoietic cells, overexpression in 
several non-hematologic cancers has been described (Supplementary Table 2). For example, 
Vav1 overexpression was found in pancreatic tumor tissue and cell lines compared to normal 
pancreatic epithelial cells.119 Vav1 expression was inversely correlated with patient survival. 
RNAi silencing analyses found that Vav1 was necessary to support tumor growth in vivo and 
in vitro, and these pro-growth phenotypes were dependent on Vav1 RhoGEF activity. Vav1 
support of tumor growth was associated with Rac1 activation of the PAK1 serine/threonine 
kinase, the NF-kappaB transcription factor, and the cyclin D1 regulator of G1 cell cycle 
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progression.119 Similar expression of Vav1 has also been described in lung cancer and also 
shown to be required for tumor growth in vitro and in vivo.118
Vav1 is not the only family member to have a role in cancer: both Vav2 and Vav3 have been 
implicated. Vav2 is activated in metastatic melanoma through the chemokine receptor-ligand 
pair CXCR4-CXCL12 and promotes expression of metalloproteinases that lead to 
invasion.120 Recently, VAV3 gene transcription was found elevated primarily in estrogen and 
progesterone receptor-positive breast cancers.122 RNAi suppression analyses demonstrated 
that Vav3 was required for mouse mammary tumorigenesis and metastasis and that Vav2 
showed a synergistic role with Vav3 in breast cancer growth and metastasis. Vav2/3 
controlled a transcriptional program that involved upregulation of gene targets important for 
lung-specific metastasis. Interestingly, the abundance of Vav2/3 transcripts was modulated 
through both Rac1-dependent and -independent pathways.
The development of androgen resistance in prostate cancer cells limits the effectiveness of 
androgen-deprivation therapy. Vav3 was found to be overexpressed in prostate tumors and its 
overexpression was associated with cell line progression to androgen-independence both in 
vitro and in vivo.123–125 Vav3-driven androgen independence was RhoGEF-dependent, 
required nuclear localization,126 and was promoted in part through activation of PI3K-Akt 
signaling.127 Constitutively activated Rac1 alone could also drive androgen-independent 
growth in vitro and in vivo.125 High Vav3 protein expression was associated with disease 
progression and reduced survival, whereas RNAi depletion reduced the tumorigenic and 
metastatic growth of androgen-independent prostate tumor cells.128 Finally, suppression of 
Vav3 expression enhanced docetaxel-induced apoptosis in prostate cancer cells, further 
supporting a therapeutic value in blocking Vav3 function in prostate cancer.129
In summary, consistent with the mouse studies suggesting that the Vav isoforms exhibit both 
redundant and distinct functions in development, there appear to be Vav isoform-distinct 
functions in cancer. For example, Vav1 suppression alone was sufficient to impair growth of 
pancreatic cancer cells despite continued expression of Vav2, and Vav2 depletion did not 
alter growth.119 Thus, Vav2 cannot substitute for Vav1 in pancreatic cancer. Similarly, 
suppression of either Vav2 or Vav3 alone greatly reduced the metastatic growth of mouse 
mammary tumor cells, and concurrent ablation of both isoforms further abolished metastatic 
growth.122 The basis for why Vav2 and Vav3 may have distinct roles is not clear, since both 
activate RhoA, Rac1 and Cdc42. One possibility is that each activates spatially distinct 
subcellular pools of the Rho GTPases, leading to activation of distinct effector signaling 
networks. Another possibility is that the Vav isoforms activate an incompletely overlapping 
extended set of Rho GTPases. Analyses of RhoGEF specificity are often restricted to RhoA, 
Rac1 and Cdc42 but do not examine other family members. This tendency towards limited 
analysis of potential substrates remains an issue that needs to be addressed if the functions of 
specific RhoGEFs are to be fully understood.
RhoGEFs and other human diseases
FGD1, which encodes a Cdc42-specific RhoGEF, was originally identified as a mutated 
gene responsible for Aarskog-Scott Syndrome (ASS; also known as faciogenital 
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dysplasia).130 ASS is an X-linked recessive developmental disorder characterized by short 
stature, by facial, skeletal, and urogenital anomalies, and by mild mental retardation. The 
ASS-associated FGD1 mutations cause loss-of-function (deletion, nonsense mutations 
causing expression of truncated proteins, missense mutations in DH-PH domains) and 
account for ~20% of individuals with ASS.130,131
Loss-of-function mutations in the related FGD4 gene are associated with one type (CMT4) 
of the Charcot-Marie-Tooth (CMT) disease group.132,133 Like FGD1, FGD4 encodes a 
Cdc42-specific GEF (Fgd4/Frabin). This heterogeneous disease group is characterized by 
damage to peripheral nerves that can result in loss of sensation and atrophy of muscles in the 
feet, legs, and hands. It is one of nine genes with causal association with CMT4, an 
autosomal recessive demyelinating form of CMT.
Mutations in OBSCN, the gene encoding the RhoGEF Obscurin, have been identified in 
melanoma and glioblastoma134 and may predispose towards these cancers and towards 
hereditary myopathies.135 OBSCN mutations have also been identified by exome 
sequencing of breast and colon cancers, supporting a possible driver function in these two 
cancers.136 Obscurin is a very large protein with GEF activity for both RhoA and TC10.
Alsin, a GEF for Rac and for the Rab5 small GTPase involved in vesicular transport, is 
encoded by the gene ALS2.137–139 Loss-of-function mutations in ALS2 have been found in 
a subset of individuals with amyotrophic lateral sclerosis (ALS),140–143 a disease 
characterized by progressive movement problems and muscle wasting caused by motor 
neuron death. Accordingly, Alsin expression is highest in motor neurons of the brain. ALS2 
mutations have been associated with autosomal recessive juvenile onset ALS and the related 
conditions of infantile-onset ascending hereditary spastic paraplegia and of juvenile-onset 
primary lateral sclerosis. The exact contribution of Alsin, Rac1 and/or Rab5 to ALS diseases 
remains to be determined.
Germline gain-of-function mutations in SOS1 have been found in ~20% of individuals with 
Noonan syndrome.144,145 This syndrome is characterized by a range of distinctive facial 
characteristics, short stature, cardiac defects, bleeding disorders, skeletal malformations, and 
a diversity of other signs and symptoms. Sos1 has dual functions and can act as either a 
RacGEF or a RasGEF. However, the frequent findings in this disorder of gain-of-function 
mutations in RAS and in genes encoding its Raf effectors (BRAF and RAF1) argue that 
enhanced activity of Sos1 on Ras rather than on Rac contributes to the role of SOS1 
mutations in Noonan syndrome.143,146,147
Loss-of-function mutations in Collybistin/ARHGEF9/hPEM2, a Cdc42-specific Dbl 
RhoGEF, have been identified in patients with X-linked mental retardation associated with 
epilepsy.148–152 Collybistin expression is neuronally restricted; Collybistin is found in 
neurons throughout the adult brain and spinal cord.
Additional Dbl RhoGEFs have also been associated with biology and disease.153 Altered 
expression and mouse model knockout studies implicate Kalirin, with an N- and C-terminal 
DH domain that activate Rac1 and RhoA respectively (Figure 3), in a number of 
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neurological and cardiovascular diseases.154 These include Huntington’s Disease, 
Alzheimer’s, schizophrenia, depression, cocaine addiction and ischemic stroke.
Finally, many pathogenic bacteria employ a virulence strategy to subvert and hijack the 
function of Rho GTPases in their eukaryotic hosts. This strategy is mediated by a type III 
secretion system to inject virulence factors, or effectors, to facilitate cell invasion, 
intracellular survival, and modulation of the host immune responses.155 Among the effectors 
that target Rho GTPases are those that either mimic or antagonize the function of eukaryotic 
RhoGEFs.31 The first discovered was the Salmonella enterica serovar typhimurium protein 
SopE,156 with related RhoGEFs (SopE2, BopE2, CopE) later identified in other bacteria. 
Members of a second class of bacterial proteins that share a WxxxE sequence were first 
thought to act as straightforward Rho GTPase mimics,157 but were later found to also mimic 
RhoGEF activity. Examples include the Map protein from enteropathogenic E. coli, and 
IpgB1 and IpgB2 from Shigella flexneri, that mimic Cdc42, Rac1 and RhoA, respectively. 
These bacterial RhoGEFs lack sequence homology to the DH domain but nevertheless 
utilize a biochemical mechanism similar to that of Dbl family RhoGEFs.158 In contrast, 
another class of type III effectors antagonizes eukaryotic RhoGEF function.159 For example, 
it was determined that EspH binds directly to the DH-PH domain of multiple RhoGEFs, 
preventing their binding to Rho substrates. While the full impact of these bacterial Rho 
GTPase regulators remains to be determined, they provide yet another example of how 
aberrant RhoGEF function may contribute to human disease. Understanding the pressures 
that led to their convergent evolution may help to further define the roles of RhoGEFs in 
cancer and other diseases.
Perspectives
Given the essential involvement of Rho GTPases in virtually every aspect of normal cell 
physiology, it is not surprising that the aberrant activities of Rho GTPases are associated 
with cancer and other diseases. Since RhoGEFs are key mediators of Rho GTPase 
activation, it is also not surprising that aberrant RhoGEF activation is a major mechanism 
driving aberrant activation of their Rho GTPase targets. Finally, given the very divergent 
sequence and domain structures beyond their shared DH-PH domains, the diversity of 
mechanisms deregulating RhoGEF functions is also to be expected. Large challenges remain 
in unraveling the precise mechanisms and contributions of RhoGEFs to specific cancers and 
other diseases, but certainly improved understanding will help to promote therapeutic 
interference in their activities.
The possibility that RhoGEFs may be directly targeted is supported by the mechanism of the 
natural product brefeldin A, an ArfGEF inhibitor that binds to the interface between the Arf 
small GTPase and the catalytic domain of ArfGEF, freezing the complex in an abortive 
conformation that cannot complete nucleotide exchange.160–162 However, the significant 
conformational change seen in Arf upon association with its GEF and upon switching from 
the GDP- to GTP-bound states makes this interaction distinct from that of Rho GTPases. To 
date, there has been very limited success in developing pharmacologic inhibitors of RhoGEF 
function.4 Thus, whether potent and selective RhoGEF inhibitors can be developed remains 
to be determined. An alternative strategy for blocking RhoGEF activity has been the 
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identification of small molecules that bind the GTPase and prevent GEF stimulation. 
Antagonists of GEF activation of Rho 163–165 and Ras 166–168 have been described. Whether 
such small molecule inhibitors of protein-protein interactions can achieve the potency and 
selectivity needed for clinical efficacy remains to be determined, but it is clear that we are at 
last on the way to finding out.
Finally, with the recent successful clinical development of numerous protein kinase 
inhibitors for cancer treatment (e.g., imatinib, erlotinib, vemurafenib), perhaps the most 
promising avenues for short term success in developing RhoGEF inhibitors may be blockade 
of the protein kinases that drive RhoGEF activation or that are activated by their Rho 
GTPase substrates. These may include inhibitors of the Src family protein tyrosine 
kinases169 that activate Vav family proteins; of the PKCi serine/threonine kinase170 
responsible for Ect2 mislocalization to the cytoplasm; of PI3K171 to impair PIP3 production 
and activation of P-Rex; or of the PAK172 or ROCK173 serine/threonine kinases activated 
downstream of Rac1 or RhoA, respectively. Whether RhoGEFs themselves turn out to be 
druggable or not, their key roles in cancer warrant continued close attention to this large and 
interesting family of Rho GTPase regulators.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Rho GTPase regulation
The human Rho GTPase family is comprised of 20 members. The majority cycle between 
GDP-bound inactive and GTP-bound active states. Unlike RhoGEFs and RhoGAPs that 
possess shared domains and sequence identity, allowing precise determination of the number 
encoded in the human genome, the majority of Rho GTPase effectors lack a common well-
defined recognition domain/motif. The information here applies mainly to RhoA, Rac1, 
Cdc42 and related isoforms. Not all Rho GTPases are regulated by GEFs, GAPs and/or 
GDIs, not all are posttranslationally modified by a geranylgeranyl isoprenoid lipid, and some 
do not have known membrane targeting elements.
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Figure 2. Key discoveries linking Dbl RhoGEFs to human disease
We highlight representative discoveries in the study of RhoGEFs that link their aberrant 
function to human disease. Gain-of-function, GOF; loss-of-function, LOF.
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Figure 3. The human Dbl RhoGEF family
The 72 DH domains found within the 70 members of human Dbl family RhoGEFs were 
aligned using ClustalX174 and a phylogenetic tree was subsequently drawn using the 
program FigTree (http://tree.bio.ed.ac.uk/software/figtree/). The protein domain architecture 
for each full-length Dbl protein is shown as annotated by SMART (http://smart.embl.de/) or 
described in the published literature. Black arrowheads indicate sites of genetic truncation 
known to activate RhoGEF function, while bracketed arrowheads designate biologically or 
catalytically active fragments of a GEF. Numbers within braces next to a Dbl protein 
indicate the reported Rho GTPase specificity of the DH domain. Please refer to 
Supplementary Table 1 for other names utilized for these RhoGEFs.
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Figure 4. Mechanisms of RhoGEF activation
Shown here are the “canonical” isoforms as identified in UniProt (http://www.uniprot.org/). 
Domain structures were determined, in part, by SMART (http://smart.embl-heidelberg.de/). 
Additional domains not identified in SMART were added based on previous sequence 
analyses of Ect238, Tiam116, P-Rex57 and Vav proteins.175 The number at the right end of 
each protein indicates the number of amino acids in the full length protein. Solid triangles 
indicate the position of N-terminal truncations that result in the formation of constitutively 
activated and transforming variants of Ect2, Tiam1, and Vav1-3. The arrow indicates the site 
of initiation of the shorter Tiam2S splice variant. The % values refer to amino acid sequence 
identity for the full length protein (overall) or the isolated DH domain, when compared to 
the first isoform shown. Gain-of-function P-Rex2a truncation (Δ) or missense (*) 
transforming mutations.99 Abbreviations: Ac, acidic domain; CC, coiled-coil; CH, calponin 
homology; Clb6 region, homology to yeast Clb6 B-type cyclin; Ex, extra region; NLS, 
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nuclear localization sequence; PIP3, phosphatidylinositol (3,4,5)-triphosphate; XRCC1, 
homology to human repair protein XRCC1.
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